The US Food and Drug Administration (FDA) has cleared Boston Scientific's Infinion16 Percutaneous Lead.
The Infinion16 Percutaneous Lead is designed for use with Boston’s Precision Plus Spinal Cord Stimulator (SCS) System to treat chronic pain.
SCS leads comprise 16 stimulating contacts which deliver electrical pulses from an implantable pulse generator to the spinal cord and mask pain signals reaching the brain.
Pacific Medical Centers Interventional Pain director Marshall Bedder said he can now place 16 contacts through a single, small insertion needle with just one lead placement.
Boston Scientific Neuromodulation Division senior vice president and president Maulik Nanavaty said with the launch of the Infinion 16 Lead, the company continues its commitment to provide pain management physicians more choices to help optimize pain relief for their patients.